
## Silvana Galderisi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3157976/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	How mental health care should change as a consequence of the COVID-19 pandemic. Lancet Psychiatry,the, 2020, 7, 813-824.	3.7	1,101
2	Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet, The, 2008, 371, 1085-1097.	6.3	964
3	Toward a new definition of mental health. World Psychiatry, 2015, 14, 231-233.	4.8	383
4	The current conceptualization of negative symptoms in schizophrenia. World Psychiatry, 2017, 16, 14-24.	4.8	354
5	The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry, 2014, 13, 275-287.	4.8	346
6	EEG microstate duration and syntax in acute, medication-naÃ <sup>-</sup> ve, first-episode schizophrenia: a multi-center study. Psychiatry Research - Neuroimaging, 2005, 138, 141-156.	0.9	316
7	Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry,the, 2018, 5, 664-677.	3.7	316
8	Prevention of Psychosis. JAMA Psychiatry, 2020, 77, 755.	6.0	287
9	Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST). American Journal of Psychiatry, 2009, 166, 675-682.	4.0	284
10	The status of spectral EEG abnormality as a diagnostic test for schizophrenia. Schizophrenia Research, 2008, 99, 225-237.	1.1	255
11	Sources of cortical rhythms in adults during physiological aging: A multicentric EEG study. Human Brain Mapping, 2006, 27, 162-172.	1.9	253
12	Deconstructing Vulnerability for Psychosis: Meta-Analysis of Environmental Risk Factors for Psychosis in Subjects at Ultra High-Risk. European Psychiatry, 2017, 40, 65-75.	0.1	241
13	Oxytocin receptor polymorphisms and adult attachment style in patients with depression. Psychoneuroendocrinology, 2009, 34, 1506-1514.	1.3	221
14	Interplay Among Psychopathologic Variables, Personal Resources, Context-Related Factors, and Real-life Functioning in Individuals With Schizophrenia. JAMA Psychiatry, 2018, 75, 396.	6.0	214
15	The cortical generators of P3a and P3b: A LORETA study. Brain Research Bulletin, 2007, 73, 220-230.	1.4	210
16	Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: A WHO study. Archives of Clinical Neuropsychology, 1993, 8, 123-135.	0.3	201
17	Deficit schizophrenia: an update. World Psychiatry, 2008, 7, 143-147.	4.8	171
18	United Nations convention on the rights of persons with disabilities needs to be interpreted on the basis of scientific evidence regarding psychiatry. European Psychiatry, 2018, 51, 87-89.	0.1	166

#	Article	IF	CITATIONS
19	SchizophreniaTime to Commit to Policy Change. Schizophrenia Bulletin, 2014, 40, S165-S194.	2.3	153
20	The clinical characterization of the patient with primary psychosis aimed at personalization of management. World Psychiatry, 2021, 20, 4-33.	4.8	153
21	Categorical and dimensional approaches to negative symptoms of schizophrenia: Focus on long-term stability and functional outcome. Schizophrenia Research, 2013, 147, 157-162.	1.1	148
22	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry,the, 2018, 5, 797-807.	3.7	141
23	Persistent negative symptoms in first episode patients with schizophrenia: Results from the European First Episode Schizophrenia Trial. European Neuropsychopharmacology, 2013, 23, 196-204.	0.3	137
24	Historical, Psychopathological, Neurological, and Neuropsychological Aspects of Deficit Schizophrenia: A Multicenter Study. American Journal of Psychiatry, 2002, 159, 983-990.	4.0	127
25	The Brief Negative Symptom Scale (BNSS): Independent validation in a large sample of Italian patients with schizophrenia. European Psychiatry, 2015, 30, 641-647.	0.1	114
26	Primary and persistent negative symptoms: Concepts, assessments and neurobiological bases. Schizophrenia Research, 2017, 186, 19-28.	1.1	110
27	ls avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback. Psychological Medicine, 2015, 45, 1765-1778.	2.7	108
28	Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST). Schizophrenia Research, 2009, 115, 97-103.	1.1	107
29	Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study. Schizophrenia Research, 2009, 115, 104-114.	1.1	102
30	Cross-cultural Validation of the 5-Factor Structure of Negative Symptoms in Schizophrenia. Schizophrenia Bulletin, 2019, 45, 305-314.	2.3	99
31	The interplay among psychopathology, personal resources, contextâ€related factors and realâ€life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and nonâ€recovered patients. World Psychiatry, 2020, 19, 81-91.	4.8	96
32	Magnetic Resonance Imaging and the Prediction of Outcome in First-Episode Schizophrenia: A Review of Current Evidence and Directions for Future Research. Schizophrenia Bulletin, 2015, 41, 574-583.	2.3	94
33	EPA guidance on assessment of negative symptoms in schizophrenia. European Psychiatry, 2021, 64, e23.	0.1	94
34	Inhibition of auditory cortical responses to ipsilateral stimuli during dichotic listening: evidence from magnetoencephalography. European Journal of Neuroscience, 2004, 19, 2329-2336.	1.2	90
35	Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. JAMA Psychiatry, 2021, 78, 550.	6.0	89
36	Network Analysis Reveals the Latent Structure of Negative Symptoms in Schizophrenia. Schizophrenia Bulletin, 2019, 45, 1033-1041.	2.3	88

#	Article	IF	CITATIONS
37	Patterns of Structural MRI Abnormalities in Deficit and Nondeficit Schizophrenia. Schizophrenia Bulletin, 2007, 34, 393-401.	2.3	85
38	Evidence-Based Medicine and Electrophysiology in Schizophrenia. Clinical EEG and Neuroscience, 2009, 40, 62-77.	0.9	85
39	Primary, Enduring Negative Symptoms: An Update on Research. Schizophrenia Bulletin, 2017, 43, 730-736.	2.3	85
40	Deficit schizophrenia: An overview of clinical, biological and treatment aspects. European Psychiatry, 2009, 24, 493-500.	0.1	84
41	Neurobiological background of negative symptoms. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 543-558.	1.8	81
42	Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: a WHO study. Archives of Clinical Neuropsychology, 1993, 8, 123-35.	0.3	79
43	Ventricle-to-brain ratio in schizophrenia: a controlled follow-up study. Biological Psychiatry, 1989, 26, 756-759.	0.7	78
44	Neuropsychological Slowness in Obsessive–Compulsive Patients. British Journal of Psychiatry, 1995, 167, 394-398.	1.7	78
45	Brain Hemispheric Organization, Anxiety, and Psychoses. CNS Spectrums, 2000, 5, 58-69.	0.7	76
46	The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. European Psychiatry, 2019, 58, 1-9.	0.1	75
47	Frequency and clinical correlates of adult separation anxiety in a sample of 508 outpatients with mood and anxiety disorders. Acta Psychiatrica Scandinavica, 2010, 122, 40-46.	2.2	73
48	Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: A WHO study. Archives of Clinical Neuropsychology, 1993, 8, 123-135.	0.3	72
49	EPA guidance on treatment of negative symptoms in schizophrenia. European Psychiatry, 2021, 64, e21.	0.1	70
50	Alexithymia and Cognitive Dysfunctions in Patients with Panic Disorder. Psychotherapy and Psychosomatics, 2008, 77, 182-188.	4.0	66
51	Pathways to functional outcome in subjects with schizophrenia living in the community and their unaffected first-degree relatives. Schizophrenia Research, 2016, 175, 154-160.	1.1	66
52	Social cognition in people with schizophrenia: a cluster-analytic approach. Psychological Medicine, 2016, 46, 2717-2729.	2.7	65
53	The Specific Level of Functioning Scale: Construct validity, internal consistency and factor structure in a large Italian sample of people with schizophrenia living in the community. Schizophrenia Research, 2014, 159, 144-150.	1.1	64
54	The "Insight Paradox―in Schizophrenia: Magnitude, Moderators and Mediators of the Association Between Insight and Depression. Schizophrenia Bulletin, 2016, 42, 1225-1233.	2.3	61

#	Article	IF	CITATIONS
55	Executive hypercontrol in obsessive–compulsive disorder: electrophysiological and neuropsychological indices. Clinical Neurophysiology, 2004, 115, 1340-1348.	0.7	60
56	A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. European Neuropsychopharmacology, 2019, 29, 947-959.	0.3	60
57	Pharmaco-EEG in Psychiatry. Clinical EEG and Neuroscience, 2006, 37, 81-98.	0.9	59
58	Clinical, biological, and neuropsychological features associated with lateral ventricular enlargement in DSM-III schizophrenic disorder. Psychiatry Research, 1987, 21, 137-149.	1.7	58
59	Induced Gamma Activity and Event-Related Coherence in Schizophrenia. Clinical EEG and Neuroscience, 2007, 38, 96-104.	0.9	57
60	Double dissociation of N1 and P3 abnormalities in deficit and nondeficit schizophrenia. Schizophrenia Research, 2007, 92, 252-261.	1.1	57
61	CEEG mapping in drug-free schizophrenics. Schizophrenia Research, 1991, 6, 15-23.	1.1	56
62	Ala147Thr substitution in translocator protein is associated with adult separation anxiety in patients with depression. Psychiatric Genetics, 2009, 19, 110-111.	0.6	56
63	Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies—PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. Schizophrenia Bulletin, 2020, 46, 432-441.	2.3	56
64	No gender differences in social outcome in patients suffering from schizophrenia. European Psychiatry, 2012, 27, 406-408.	0.1	53
65	Disorganization and real-world functioning in schizophrenia: Results from the multicenter study of the Italian Network for Research on Psychoses. Schizophrenia Research, 2018, 201, 105-112.	1.1	52
66	Clinical and neuropsychological correlates of cerebral ventricular enlargement in schizophrenia. Journal of Psychiatric Research, 1985, 19, 587-596.	1.5	51
67	Catechol-O-Methyltransferase Val <sup>158</sup> Met Polymorphism in Schizophrenia: Associations with Cognitive and Motor Impairment. Neuropsychobiology, 2005, 52, 83-89.	0.9	51
68	QEEG alpha1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients. Biological Psychiatry, 1994, 35, 367-374.	0.7	50
69	Neurocognitive functioning in subjects with eating disorders: the influence of neuroactive steroids. Biological Psychiatry, 2003, 53, 921-927.	0.7	50
70	Transcranial direct current stimulation for hyperactivity and noncompliance in autistic disorder. World Journal of Biological Psychiatry, 2015, 16, 361-366.	1.3	50
71	Stereotaxy-Based Regional Brain Volumetry Applied to Segmented MRI: Validation and Results in Deficit and Nondeficit Schizophrenia. NeuroImage, 2002, 17, 373-384.	2.1	49
72	Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma. Psychiatry Research, 2017, 256, 359-364.	1.7	49

#	Article	IF	CITATIONS
73	Modified nutritional counselling to increase motivation to treatment in anorexia nervosa. European Psychiatry, 2005, 20, 186-187.	0.1	48
74	Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study. Schizophrenia Research, 2013, 147, 132-139.	1.1	48
75	Social skills and neurocognitive individualized training in schizophrenia: comparison with structured leisure activities. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 305-315.	1.8	47
76	Reward anticipation and trait anhedonia: An electrophysiological investigation in subjects with schizophrenia. Clinical Neurophysiology, 2016, 127, 2149-2160.	0.7	45
77	The complex relationship between self-reported â€~personal recovery' and clinical recovery in schizophrenia. Schizophrenia Research, 2018, 192, 108-112.	1.1	45
78	Premorbid academic and social functioning in patients with schizophrenia and its associations with negative symptoms and cognition. Acta Psychiatrica Scandinavica, 2018, 138, 253-266.	2.2	44
79	COMT Val158Met and BDNF C270T polymorphisms in schizophrenia: a case-control study. Schizophrenia Research, 2005, 73, 27-30.	1.1	42
80	Neurophysiological correlates of Avolition-apathy in schizophrenia: A resting-EEG microstates study. Neurolmage: Clinical, 2018, 20, 627-636.	1.4	39
81	Hemispheric asymmetry and psychopathological dimensions in drug-free patients with schizophrenia. International Journal of Psychophysiology, 1999, 34, 293-301.	0.5	38
82	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). European Neuropsychopharmacology, 2019, 29, 1301-1311.	0.3	38
83	Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives. Psychological Medicine, 2018, 48, 1359-1366.	2.7	37
84	Computerized EEG topography findings in schizophrenic patients before and after haloperidol treatment. International Journal of Psychophysiology, 1992, 13, 283-290.	0.5	35
85	Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review. Frontiers in Psychiatry, 2021, 12, 789179.	1.3	35
86	Neurocognitive indices of executive hypercontrol in obsessive?compulsive disorder. Acta Psychiatrica Scandinavica, 2007, 115, 380-387.	2.2	34
87	The relationships of personal resources with symptom severity and psychosocial functioning in persons with schizophrenia: results from the Italian Network for Research on Psychoses study. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 285-294.	1.8	33
88	Electrophysiological Aberrations Associated with Negative Symptoms in Schizophrenia. Current Topics in Behavioral Neurosciences, 2014, 21, 129-156.	0.8	32
89	Functional connectivity of the ventral tegmental area and avolition in subjects with schizophrenia: a resting state functional MRI study. European Neuropsychopharmacology, 2018, 28, 589-602.	0.3	32
90	Relationship between CSF noradrenaline levels, Câ€EEG indicators of activation and psychosis ratings in drugâ€free schizophrenic patients. Acta Psychiatrica Scandinavica, 1985, 71, 19-24.	2.2	31

#	Article	IF	CITATIONS
91	Transcranial Direct Current Stimulation for Autistic Disorder. Biological Psychiatry, 2014, 76, e5-e6.	0.7	31
92	Dissecting negative symptoms of schizophrenia: History, assessment, pathophysiological mechanisms and treatment. Schizophrenia Research, 2017, 186, 1-2.	1.1	31
93	Avolition-Apathy and White Matter Connectivity in Schizophrenia: Reduced Fractional Anisotropy Between Amygdala and Insular Cortex. Clinical EEG and Neuroscience, 2018, 49, 55-65.	0.9	31
94	Dorsolateral prefrontal cortex volume in patients with deficit or nondeficit schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 37, 264-269.	2.5	30
95	Shall we really say goodbye to first rank symptoms?. European Psychiatry, 2016, 37, 8-13.	0.1	30
96	Categorizing and assessing negative symptoms. Current Opinion in Psychiatry, 2017, 30, 201-208.	3.1	30
97	The association between insight and depressive symptoms in schizophrenia: Undirected and Bayesian network analyses. European Psychiatry, 2020, 63, 1-21.	0.1	30
98	Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning. European Neuropsychopharmacology, 2020, 34, 76-86.	0.3	30
99	A proposed new definition of mental health. Psychiatria Polska, 2017, 51, 407-411.	0.2	29
100	Value of schizophrenia treatment I: The patient journey. European Psychiatry, 2018, 53, 107-115.	0.1	28
101	A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia. International Journal of Neuropsychopharmacology, 2022, 25, 238-251.	1.0	28
102	Conditional Associative Learning in Drug-Free Schizophrenic Patients. Neuropsychobiology, 1987, 17, 30-34.	0.9	27
103	Neurocognitive functioning in bulimia nervosa: the role of neuroendocrine, personality and clinical aspects. Psychological Medicine, 2011, 41, 839-848.	2.7	26
104	Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective. Psychological Medicine, 2012, 42, 1461-1473.	2.7	26
105	Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-α gene (PPARA) and schizophrenia. European Neuropsychopharmacology, 2013, 23, 749-759.	0.3	26
106	Characterization of premorbid functioning during childhood in patients with deficit vs. non-deficit schizophrenia and in their healthy siblings. Schizophrenia Research, 2016, 174, 172-176.	1.1	25
107	Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions. Psychiatry Research - Neuroimaging, 1996, 67, 113-122.	0.9	24
108	NRG1 and BDNF genes in schizophrenia: An association study in an Italian case-control sample. Psychiatry Research, 2010, 176, 82-84.	1.7	24

#	Article	IF	CITATIONS
109	Neurocognitive individualized training versus social skills individualized training: A randomized trial in patients with schizophrenia. Schizophrenia Research, 2013, 150, 69-75.	1.1	24
110	Cerebral connectivity and psychotic personality traits. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 292-299.	1.8	23
111	Disorganization and cognitive impairment in schizophrenia: New insights from electrophysiological findings. International Journal of Psychophysiology, 2019, 145, 99-108.	0.5	23
112	Primary prevention of depression: An umbrella review of controlled interventions. Journal of Affective Disorders, 2021, 294, 957-970.	2.0	23
113	The reliability and clinical utility of ICD-11 schizoaffective disorder: A field trial. Schizophrenia Research, 2019, 208, 235-241.	1.1	22
114	Decrease of functional coupling between left and right auditory cortices during dichotic listening: An electroencephalography study. Neuroscience, 2005, 136, 323-332.	1.1	21
115	Pharmaco-EEG: A History of Progress and a Missed Opportunity. Clinical EEG and Neuroscience, 2006, 37, 61-65.	0.9	21
116	The influence of autistic symptoms on social and non-social cognition and on real-life functioning in people with schizophrenia: Evidence from the Italian Network for Research on Psychoses multicenter study. European Psychiatry, 2020, 63, e98.	0.1	20
117	Transitions in mental health care: The European Psychiatric Association contribution to reform in Bulgaria. European Psychiatry, 2020, 63, 1-13.	0.1	20
118	A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa. European Psychiatry, 2021, 64, e71.	0.1	20
119	Lateralization patterns of verbal stimuli processing assessed by reaction time and event-related potentials in schizophrenic patients. International Journal of Psychophysiology, 1988, 6, 167-176.	0.5	19
120	Qualitative MRI findings in patients with schizophrenia: a controlled study. Psychiatry Research - Neuroimaging, 2000, 98, 117-126.	0.9	19
121	Factors associated with increased noradrenaline levels in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1990, 14, 49-59.	2.5	18
122	Accuracy of self-assessment of real-life functioning in schizophrenia. NPJ Schizophrenia, 2021, 7, 11.	2.0	18
123	Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life― Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 109, 110250.	2.5	18
124	Negative Symptoms of Schizophrenia and Dopaminergic Transmission: Translational Models and Perspectives Opened by iPSC Techniques. Frontiers in Neuroscience, 2020, 14, 632.	1.4	17
125	â€~Simple schizophrenia': a controlled MRI and clinical/neuropsychological study. Psychiatry Research - Neuroimaging, 1999, 91, 175-184.	0.9	16
126	Hemispheric lateralization patterns and psychotic experiences in healthy subjects. Psychiatry Research - Neuroimaging, 2005, 139, 141-154.	0.9	16

8

#	Article	IF	CITATIONS
127	Acute Effects of Music Therapy in Subjects With Psychosis During Inpatient Treatment. Psychiatry (New York), 2018, 81, 218-227.	0.3	16
128	C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment. European Neuropsychopharmacology, 1990, 1, 51-54.	0.3	15
129	Brain electrical microstates in subjects with panic disorder. Brain Research Bulletin, 2001, 54, 427-435.	1.4	15
130	Attitudes of patients with schizophrenia and depression to psychiatric research: a study in seven European countries. Social Psychiatry and Psychiatric Epidemiology, 2011, 46, 159-165.	1.6	15
131	The interrelation of needs and quality of life in first-episode schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 207-216.	1.8	15
132	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. European Psychiatry, 2021, 64, e7.	0.1	15
133	Improving Knowledge on Pathways to Functional Outcome in Schizophrenia: Main Results From the Italian Network for Research on Psychoses. Frontiers in Psychiatry, 2021, 12, 791117.	1.3	15
134	Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia. Expert Review of Neurotherapeutics, 2022, 22, 541-555.	1.4	15
135	Lateralization patterns of event-related potential and performance indices in schizophrenia: relationship to clinical state and neuroleptic treatment. International Journal of Psychophysiology, 1991, 10, 225-230.	0.5	13
136	Emotions, Brain Development, and Psychopathologic Vulnerability. CNS Spectrums, 2000, 5, 44-48.	0.7	13
137	Physiological Correlates of Positive Symptoms in Schizophrenia. Current Topics in Behavioral Neurosciences, 2014, 21, 103-128.	0.8	13
138	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study. Frontiers in Psychiatry, 2022, 13, 826465.	1.3	13
139	Cognitive-enhancing effects of aripiprazole: a case report. Clinical Practice and Epidemiology in Mental Health, 2008, 4, 24.	0.6	12
140	SoCIAL – training cognition in schizophrenia: a pilot study. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 1947-1956.	1.0	12
141	Assessment of de novo copy-number variations in Italian patients with schizophrenia: Detection of putative mutations involving regulatory enhancer elements. World Journal of Biological Psychiatry, 2019, 20, 126-136.	1.3	12
142	Can IQ moderate the response to cognitive remediation in people with schizophrenia?. Journal of Psychiatric Research, 2021, 133, 38-45.	1.5	12
143	Investigating the Relationships of P3b with Negative Symptoms and Neurocognition in Subjects with Chronic Schizophrenia. Brain Sciences, 2021, 11, 1632.	1.1	12
144	Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia – data from the OPTiMiSE trial. Psychiatry Research, 2020, 289, 112970.	1.7	11

#	Article	IF	CITATIONS
145	Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia. Schizophrenia Research, 2021, 228, 29-35.	1.1	11
146	Investigating the Relationship between White Matter Connectivity and Motivational Circuits in Subjects with Deficit Schizophrenia: A Diffusion Tensor Imaging (DTI) Study. Journal of Clinical Medicine, 2022, 11, 61.	1.0	10
147	Value of schizophrenia treatment II: Decision modelling for developing early detection and early intervention services in the Czech Republic. European Psychiatry, 2018, 53, 116-122.	0.1	9
148	Schizophrenia and "unmet needs― From diagnosis to care in Italy. European Psychiatry, 2020, 63, e26.	0.1	9
149	Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study. Schizophrenia Bulletin, 2021, 47, 444-455.	2.3	9
150	We are not ready to abandon the current schizophrenia construct, but should be prepared to do so. Schizophrenia Research, 2022, 242, 30-34.	1.1	9
151	Tracing Links Between Early Auditory Information Processing and Negative Symptoms in Schizophrenia: An ERP Study. Frontiers in Psychiatry, 2021, 12, 790745.	1.3	9
152	Impulsiveness in Patients with Bulimia Nervosa: Electrophysiological Evidence of Reduced Inhibitory Control. Neuropsychobiology, 2013, 68, 116-123.	0.9	8
153	Impact of Reward and Loss Anticipation on Cognitive Control: An Event-Related Potential Study in Subjects With Schizophrenia and Healthy Controls. Clinical EEG and Neuroscience, 2018, 49, 46-54.	0.9	8
154	Beyond the Transnosographic Emphasis on Psychosis: Nosological Perspectives on Schizophrenia and Its Prevention. Frontiers in Psychiatry, 2019, 10, 666.	1.3	8
155	Mismatch Negativity and P3a Impairment through Different Phases of Schizophrenia and Their Association with Real-Life Functioning. Journal of Clinical Medicine, 2021, 10, 5838.	1.0	8
156	A functional comparison of patients with schizophrenia between the North and South of Europe. European Psychiatry, 2012, 27, 442-444.	0.1	7
157	Autism Rating Scale: A New Tool for Characterizing the Schizophrenia Phenotype. Frontiers in Psychiatry, 2021, 12, 622359.	1.3	7
158	Correspondence. Schizophrenia Research, 1995, 14, 265-266.	1.1	6
159	Familial sinistrality and handedness in patients with first episode schizophrenia: The EUFEST study. Laterality, 2012, 17, 217-224.	0.5	6
160	<p>The Efficacy, Feasibility And Acceptability Of A Remotely Accessible Use Of CIRCuiTS, A Computerized Cognitive Remediation Therapy Program For Schizophrenia: A Pilot Study</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 3103-3113.	1.0	6
161	â€~Precision psychiatry' needs to become part of â€~personalized psychiatry'. Fortschritte Der Neurologie Psychiatrie, 2020, 88, 767-772.	0.3	6
162	Factors influencing lithium versus valproate prescription preference in the maintenance treatment of bipolar patients: a report from the Italian Early Career Psychiatrists (SOPSI-GG). International Journal of Psychiatry in Clinical Practice, 2021, 25, 82-89.	1.2	6

#	Article	IF	CITATIONS
163	Negative symptoms in First-Episode Schizophrenia related to morphometric alterations in orbitofrontal and superior temporal cortex: the OPTiMiSE study. Psychological Medicine, 2023, 53, 3471-3479.	2.7	6
164	Factors associated with decreased platelet MAO activity in chronic schizophrenics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1987, 11, 79-86.	2.5	5
165	Motion standstill leads to activation of inferior parietal lobe. Human Brain Mapping, 2006, 27, 340-349.	1.9	5
166	The UN Convention on the Rights of Persons with Disabilities: great opportunities and dangerous interpretations. World Psychiatry, 2019, 18, 47-48.	4.8	5
167	Abnormal bodily experiences detected by Abnormal Bodily Phenomena questionnaire are more frequent and severe in schizophrenia than in bipolar disorder with psychotic features. European Psychiatry, 2020, 63, e49.	0.1	5
168	The Cognitive Assessment Interview (CAI): Association with neuropsychological scores and real-life functioning in a large sample of Italian subjects with schizophrenia. Schizophrenia Research, 2022, 241, 161-170.	1.1	5
169	Physiologic Basis of the EEG Signal. , 2011, , 7-12.		4
170	Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia. BMJ, The, 2016, 354, i4728.	3.0	4
171	Untangling the Factors Contributing to Functional Outcome in Schizophrenia—Reply. JAMA Psychiatry, 2018, 75, 754.	6.0	4
172	Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia. World Journal of Biological Psychiatry, 2022, 23, 46-54.	1.3	4
173	ITAlian Partnership for Psychosis Prevention (ITAPP): improving the mental health of young people. European Psychiatry, 2021, 64, 1-21.	0.1	4
174	Psychophysiology in psychiatry: new perspectives in the study of mental disorders. World Psychiatry, 2002, 1, 166-8.	4.8	4
175	Joint structural-functional magnetic resonance imaging features are associated with diagnosis and real-world functioning in patients with schizophrenia. Schizophrenia Research, 2022, 240, 193-203.	1.1	4
176	Negative Symptom Domains in Children and Adolescents at Ultra-High Risk for Psychosis: Association With Real-Life Functioning. Schizophrenia Bulletin Open, 2022, 3, .	0.9	4
177	Scalability of the Positive and Negative Syndrome Scale in firstâ€episode schizophrenia assessed by Rasch models. Acta Psychiatrica Scandinavica, 2022, 146, 21-35.	2.2	4
178	Searching for bridges between psychopathology and real-world functioning in first-episode psychosis: A network analysis from the OPTiMiSE trial. European Psychiatry, 2022, 65, .	0.1	4
179	The added value of including cognitive impairment in the diagnostic criteria for schizophrenia. World Psychiatry, 2008, 7, 36-37.	4.8	3
180	Current trends in diagnosis and treatment of mental disorders. European Psychiatry, 2018, 50, 4-6.	0.1	3

#	Article	IF	CITATIONS
181	Neuroimaging and Psychopathological Domains. , 2019, , 57-155.		3
182	Clinical applications of pharmaco-EEG in psychiatry: the prediction of response to treatment with antipsychotics. Methods and Findings in Experimental and Clinical Pharmacology, 2002, 24 Suppl C, 85-9.	0.8	3
183	Facial emotion recognition impairment is related to disorganisation in multi-episode schizophrenia. Schizophrenia Research: Cognition, 2014, 1, 122-125.	0.7	2
184	The second-generation assessment scales: Brief negative symptom scale and clinical assessment interview for negative symptoms. European Psychiatry, 2016, 33, S70-S70.	0.1	2
185	Social Cognition Individualized Activities Lab for Social Cognition Training and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-Life Functioning (Prot. n°: NCT05130853). Frontiers in Psychiatry, 2022, 13, 833550.	1.3	2
186	Quantitative EEG reactivity to neuroleptic challenge in first-episode and chronic schizophrenics. Biological Psychiatry, 1997, 42, 64S.	0.7	1
187	Neurophysiological Research in Psychiatry. , 0, , 125-180.		1
188	DEFICIT SCHIZOPHRENIA: A VALID CATEGORICAL SUBTYPE OF SCHIZOPHRENIA?. Schizophrenia Research, 2008, 102, 45.	1.1	1
189	Effects of antipsychotics on cognitive functions: an ERP study in healthy controls. European Psychiatry, 2011, 26, 1267-1267.	0.1	1
190	EEG in Delirium and Dementia. , 2011, , 147-162.		1
191	Standard EEG in Personality and Anxiety Disorders. , 2011, , 133-146.		1
192	Social skills vs. Neurocognitive training in psychotic patients. European Psychiatry, 2011, 26, 1475-1475.	0.1	1
193	Neurophysiological correlates of negative symptom domains: an auditory oddball study in schizophrenia. European Neuropsychopharmacology, 2016, 26, S506-S507.	0.3	1
194	Relationships between neurocognition, social cognition and functional outcome in schizophrenia. European Psychiatry, 2016, 33, S67-S67.	0.1	1
195	EPA position paper: Improving the image of psychiatry and psychiatrists. European Psychiatry, 2017, 42, 24-26.	0.1	1
196	Resilience in people with schizophrenia. Results from the Italian Network for Research on Psychoses. European Journal of Public Health, 2017, 27, .	0.1	1
197	Psychiatry and psychiatrists: Fourteen core statements. European Psychiatry, 2018, 52, 136-138.	0.1	1
198	Toward Clinical Translation of Neuroimaging Research in Schizophrenia and Other Primary Psychotic Disorders. , 2019, , 327-345.		1

#	Article	IF	CITATIONS
199	Neuroimaging: Diagnostic Boundaries and Biomarkers. , 2019, , 1-56.		1
200	Neglected Vulnerabilities in Mental Health: Where Do We Need to Do More?. , 2022, , 335-369.		1
201	Determinants of Clinical Recovery in Schizophrenia. Comprehensive Approach To Psychiatry, 2022, , 23-43.	0.7	1
202	Quantitative EEG in Psychiatry: From Research to Clinical Applications. European Psychiatry, 1997, 12, 105s-105s.	0.1	0
203	EEG mapping before and after antipsychotic treatment in chronic and first-episode schizophrenics. European Psychiatry, 1998, 13, 197S-197S.	0.1	0
204	S21.02 Cognitive dysfunctions in psychotic patients: Relationship with symptoms and antipsychotic treatment. European Psychiatry, 2000, 15, 252s-252s.	0.1	0
205	Psychophysiology of Mood Disorders. , 0, , 777-790.		0
206	CS06-03 - Relationship between cognition and psychopathology. European Psychiatry, 2011, 26, 1788-1788.	0.1	0
207	Which Outcome Indices Would Clinicians Like to See in Schizophrenia Clinical Trials?. European Psychiatry, 2011, 26, 2204-2204.	0.1	0
208	Primary and enduring negative symptoms in first episode and chronic patients with schizophrenia. European Psychiatry, 2011, 26, 2068-2068.	0.1	0
209	Perception of body shape in bulimia nervosa: An ERP study. European Psychiatry, 2011, 26, 741-741.	0.1	0
210	Negative symptoms domains: pathways to functional outcome in schizophrenia. European Neuropsychopharmacology, 2016, 26, S123.	0.3	0
211	Electrophysiological mechanisms underlying ERP amplitude reduction in patients with schizophrenia: A time-frequency analysis. European Psychiatry, 2016, 33, S104-S104.	0.1	0
212	The social cognition individualized activities lab: Implementation of a new remediation intervention for social cognition. European Psychiatry, 2016, 33, S567-S567.	0.1	0
213	A comprehensive systematic screening protocol for assessment of medical comorbidities in schizophrenia. European Psychiatry, 2016, 33, S574-S574.	0.1	0
214	Relation between EEG source functional connectivity and the negative symptom severity in schizophrenia: a preliminary report from a multicentre study. European Psychiatry, 2016, 33, s246-s246.	0.1	0
215	Editorial: The EPA, Brexit and beyond. European Psychiatry, 2017, 42, 27-28.	0.1	0
216	Effects of chronic antipsychotic treatment on neurophysiological correlates of the auditory oddball task in schizophrenia: A preliminary report from a multicentre study. European Psychiatry, 2017, 41, S192-S192.	0.1	0

#	Article	IF	CITATIONS
217	Functional connectivity of the ventral tegmental area and avolition in schizophrenia: A resting state functional MRI study. European Psychiatry, 2017, 41, S196-S196.	0.1	0
218	Electrophysiological Correlates of Negative Symptom Domains in Schizophrenia. European Psychiatry, 2017, 41, S96-S97.	0.1	0
219	Disorganization in Schizophrenia: A Resting EEG Study. European Psychiatry, 2017, 41, S100-S100.	0.1	0
220	Future coordination and integration of the results of the EU funded projects on schizophrenia and other mental disorders. European Psychiatry, 2018, 50, 1-3.	0.1	0
221	White matter structural connectivity abnormalities in subjects with deficit schizophrenia: A diffusion tensor imaging study. European Neuropsychopharmacology, 2019, 29, S110.	0.3	0
222	Academic and social functioning in early life epochs in schizophrenia patients and first-degree unaffected relatives. European Neuropsychopharmacology, 2019, 29, S336.	0.3	0
223	Questionnaire on Attitude towards Research and Care (QuARC): a survey of patients with psychosis. Journal of Mental Health, 2020, 29, 590-596.	1.0	0
224	P.778 Electrophysiological indices and expressive deficit domain of negative symptoms in subjects with schizophrenia. European Neuropsychopharmacology, 2020, 40, S442.	0.3	0
225	P.307 Resting state MRI functional connectivity and negative symptoms in subjects with schizophrenia. European Neuropsychopharmacology, 2021, 44, S44-S45.	0.3	0
226	Selected E-ISNR 2004 Conference Presentation Abstracts. Journal of Neurotherapy, 2005, 9, 103-108.	0.9	0
227	Haloperidol-Induced Changes of Computerized Electroencephalogram Topography in Drug-Free Schizophrenic Patients. , 1993, , 245-250.		0
228	Predicting response to antipsychotics by electrophysiological indices. Methods and Findings in Experimental and Clinical Pharmacology, 2002, 24 Suppl D, 79.	0.8	0
229	P.0589 Resting-state functional connectivity of the ventral tegmental area and negative symptoms in subjects with schizophrenia: a resting-state functional MRI study. European Neuropsychopharmacology, 2021, 53, S431-S432.	0.3	0
230	P.0592 Investigating the relationships of N100-P3b with symptom dimensions and cognitive impairments in subjects with chronic schizophrenia. European Neuropsychopharmacology, 2021, 53, S432-S433.	0.3	0